US 11,857,539 B2
Gel ophthalmic formulations of pilocarpine and brimonidine compounds and related methods
Mandar V. Shah, Rockaway, NJ (US); Ilango Subramanian, Warren, NJ (US); Veerappan Subramanian, Warren, NJ (US); and Aman Trehan, Hillsborough, NJ (US)
Assigned to Somerset Therapeutics, LLC, Hollywood, FL (US)
Filed by Somerset Therapeutics, LLC, Hollywood, FL (US)
Filed on Feb. 9, 2023, as Appl. No. 18/167,059.
Claims priority of provisional application 63/308,382, filed on Feb. 9, 2022.
Claims priority of provisional application 63/308,394, filed on Feb. 9, 2022.
Claims priority of provisional application 63/308,418, filed on Feb. 9, 2022.
Claims priority of provisional application 63/308,402, filed on Feb. 9, 2022.
Claims priority of provisional application 63/308,417, filed on Feb. 9, 2022.
Claims priority of provisional application 63/308,390, filed on Feb. 9, 2022.
Prior Publication US 2023/0248701 A1, Aug. 10, 2023
Int. Cl. A61K 31/4178 (2006.01); A61K 31/498 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 31/14 (2006.01); A61K 47/44 (2017.01)
CPC A61K 31/4178 (2013.01) [A61K 9/0048 (2013.01); A61K 31/14 (2013.01); A61K 31/498 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01)] 22 Claims
 
1. A pharmaceutically acceptable and ophthalmologically suitable gel composition for treating an ocular condition via administration to a mammalian eye, the composition comprising (1) a pilocarpine compound in an amount greater than 1% w/v; (2) a brimonidine compound in an amount of between 0.05% w/v and 0.2% w/v, and (3) at least one polyethoxylated castor oil, wherein the w/v ratio of the at least one polyethoxylated castor oil to the brimonidine compound is between about 1:0.06 and about 1:4.